Literature DB >> 19198561

Measles virus and CD46.

C Kemper1, J P Atkinson.   

Abstract

Measles virus (MV) was isolated in 1954 (Enders and Peeble 1954). It is among the most contagious of viruses and a leading cause of mortality in children in developing countries (Murray and Lopez 1997; Griffin 2001; Bryce et al. 2005). Despite intense research over decades on the biology and pathogenesis of the virus and the successful development in 1963 of an effective MV vaccine (Cutts and Markowitz 1994), cell entry receptor(s) for MV remained unidentified until 1993. Two independent studies showed that transfection of nonsusceptible rodent cells with human CD46 renders these cells permissive to infection with the Edmonston and Halle vaccine strains of measles virus (Dorig et al. 1993; Naniche et al. 1993). A key finding in these investigations was that MV binding and infection was inhibited by monoclonal and polyclonal antibodies to CD46. These reports established CD46 as a MV cell entry receptor. This chapter summarizes the role of CD46 in measles virus infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19198561     DOI: 10.1007/978-3-540-70523-9_3

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  12 in total

1.  Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model.

Authors:  Yuan Qi; Kailin Xing; Lanlin Zhang; Fangyu Zhao; Ming Yao; Aiqun Hu; Xianghua Wu
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-06       Impact factor: 4.553

2.  Wild-type measles virus with the hemagglutinin protein of the edmonston vaccine strain retains wild-type tropism in macaques.

Authors:  Kaoru Takeuchi; Noriyo Nagata; Sei-Ich Kato; Yasushi Ami; Yuriko Suzaki; Tadaki Suzuki; Yuko Sato; Yasuko Tsunetsugu-Yokota; Kazuyasu Mori; Nguyen Van Nguyen; Hideki Kimura; Kyosuke Nagata
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 3.  Measles virus.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 4.  Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies.

Authors:  Thomas A Bowden; Max Crispin; E Yvonne Jones; David I Stuart
Journal:  Biochem Soc Trans       Date:  2010-10       Impact factor: 5.407

5.  Measles virus causes immunogenic cell death in human melanoma.

Authors:  O G Donnelly; F Errington-Mais; L Steele; E Hadac; V Jennings; K Scott; H Peach; R M Phillips; J Bond; H Pandha; K Harrington; R Vile; S Russell; P Selby; A A Melcher
Journal:  Gene Ther       Date:  2011-12-15       Impact factor: 5.250

6.  The Reorientation of T-Cell Polarity and Inhibition of Immunological Synapse Formation by CD46 Involves Its Recruitment to Lipid Rafts.

Authors:  Mandy J Ludford-Menting; Blessing Crimeen-Irwin; Jane Oliaro; Anupama Pasam; David Williamson; Natalie Pedersen; Patricia Guillaumot; Dale Christansen; Serge Manie; Katharina Gaus; Sarah M Russell
Journal:  J Lipids       Date:  2011-01-20

7.  Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus.

Authors:  Ryan S Noyce; Daniel G Bondre; Michael N Ha; Liang-Tzung Lin; Gary Sisson; Ming-Sound Tsao; Christopher D Richardson
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

8.  Measles virus hemagglutinin: structural insights into cell entry and measles vaccine.

Authors:  Takao Hashiguchi; Katsumi Maenaka; Yusuke Yanagi
Journal:  Front Microbiol       Date:  2011-12-16       Impact factor: 5.640

Review 9.  Complement regulator CD46: genetic variants and disease associations.

Authors:  M Kathryn Liszewski; John P Atkinson
Journal:  Hum Genomics       Date:  2015-06-10       Impact factor: 4.639

Review 10.  The Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) Protein.

Authors:  Liang-Tzung Lin; Christopher D Richardson
Journal:  Viruses       Date:  2016-09-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.